Adakveo (crizanlizumab) is the first and only FDA-approved intravenous (IV) infusion used to lower the number of pain crises in people with sickle cell disease. After your first month of treatment, you only need to get the infusions once a month. But you have to receive it at your provider's office. This medication is brand name only and can be expensive.
Adakveo (crizanlizumab) is a monoclonal antibody that binds to P-selectin, which is a sticky protein that normally plays a role in blocking blood flow.
In people with sickle cell anemia, P-selectin gets activated when blood vessels are damaged by the sickled red blood cells. This causes your red blood cells, white blood cells, and platelets to stick together and block blood flow, which results in pain crises.
By binding to P-selectin, Adakveo (crizanlizumab) stops your blood cells from sticking together. This means your blood can flow better, which lowers the amount of pain crises.
The following side effects may get better over time as your body gets used to the medication. Let your healthcare provider know immediately if you continue to experience these symptoms or if they worsen over time.
Contact your healthcare provider immediately if you experience any of the following.
Side effects that you should report to your care team as soon as possible:
Side effects that usually do not require medical attention (report these to your care team if they continue or are bothersome):
If you miss your Adakveo (crizanlizumab) infusion appointment, contact your provider right away to reschedule. If you can get rescheduled within 2 weeks, you should be able to get back on track with your usual dosing schedule. If you get rescheduled more than 2 weeks after your missed dose, then your monthly dosing schedule will need to be adjusted according to the rescheduled dose.
Hydroxyurea is a common medication used to help keep your red blood cells from turning into a sickle shape, which helps manage pain crises in people with sickle cell disease. As long as your provider recommends it, you may continue to take hydroxyurea while getting monthly Adakveo (crizanlizumab) infusions.
It's not known if Adakveo (crizanlizumab) is safe or works well in children 15 years of age and younger. Talk with your child's provider about other treatment options for them.
There isn't much research done in human pregnancies. But based on information from studies done on animals, Adakveo (crizanlizumab) can cause harm to your unborn baby including death. If you're pregnant or planning to become pregnant, talk with your provider about the risks and benefits of this medication.
Your Adakveo (crizanlizumab) infusion should take about 30 minutes. It's given through your vein in your healthcare provider's office.
Adakveo (crizanlizumab) can cause some serious health issues. This risk may be even higher for certain groups. If this worries you, talk to your doctor or pharmacist about other options.
Adakveo (crizanlizumab) can cause you to have a reaction either during the infusion or even up to 24 hours after you've received the infusion. This is most likely to happen after your first or second infusion. In many cases, your provider can slow down the rate of your infusion, or give you medication to manage your infusion-related symptoms. If the reaction is severe enough (e.g., hives, shortness of breath), your provider might stop the infusion altogether. Let your provider know right away if you develop pain in your body, headache, fever, chills or shivering, feeling sick to your stomach, diarrhea, difficulty breathing, or dizziness.
Make sure to tell all of your healthcare providers that you're receiving Adakveo (crizanlizumab) before getting certain blood tests drawn. Adakveo (crizanlizumab) can interfere with the results of a laboratory test commonly used to measure your platelet counts.
Adakveo (crizanlizumab) is only available as an intravenous (IV) infusion that's administered by a healthcare provider.
Your dose of Adakveo (crizanlizumab) depends on your weight. In general, the typical dose is 5 mg/kg, given as an IV infusion over a period of 30 minutes, at Week 0, Week 2, and then every 4 weeks thereafter.